secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001654954-22-009385
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience adopts staggered board, eliminates shareholder written consent
------------------------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws effective June 30, 2022.
- Creates three-class staggered board; only one class elected per annual meeting after initial election.
- Eliminates stockholder ability to take action by written consent.
- Only the Board may appoint directors to fill vacancies or change the number of directors.
- Adds modernizing provisions for electronic meetings and access to corporate records.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/0001654954-22-009385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422009385/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-009385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer